3.62
前日終値:
$3.71
開ける:
$3.68
24時間の取引高:
456.42K
Relative Volume:
0.73
時価総額:
$167.71M
収益:
$20.72M
当期純損益:
$-100.84M
株価収益率:
-1.3609
EPS:
-2.66
ネットキャッシュフロー:
$-78.56M
1週間 パフォーマンス:
+3.72%
1か月 パフォーマンス:
+11.73%
6か月 パフォーマンス:
-53.83%
1年 パフォーマンス:
-85.31%
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
名前
4 D Molecular Therapeutics Inc
セクター
電話
(510) 505-2680
住所
5858 HORTON STREET #455, EMERYVILLE
FDMT を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
FDMT
4 D Molecular Therapeutics Inc
|
3.62 | 161.67M | 20.72M | -100.84M | -78.56M | -2.66 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-01-13 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
2024-11-21 | 開始されました | Morgan Stanley | Underweight |
2024-09-23 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
2024-04-15 | 開始されました | Barclays | Overweight |
2024-02-07 | 再開されました | Goldman | Buy |
2023-10-26 | 開始されました | RBC Capital Mkts | Outperform |
2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
2023-10-18 | アップグレード | Leerink Partners | Market Perform → Outperform |
2023-07-05 | 開始されました | Chardan Capital Markets | Buy |
2023-01-30 | 開始されました | BMO Capital Markets | Outperform |
2022-11-18 | 開始されました | H.C. Wainwright | Buy |
2022-11-15 | アップグレード | Goldman | Neutral → Buy |
2022-08-12 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
2022-06-22 | 開始されました | Jefferies | Buy |
2022-01-04 | 開始されました | SVB Leerink | Outperform |
2021-01-05 | 開始されました | BofA Securities | Buy |
2021-01-05 | 開始されました | Evercore ISI | Outperform |
2021-01-05 | 開始されました | Goldman | Neutral |
すべてを表示
4 D Molecular Therapeutics Inc (FDMT) 最新ニュース
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
D. E. Shaw & Co. Inc. Grows Stake in Nektar Therapeutics (NASDAQ:NKTR) - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Position Lowered by D. E. Shaw & Co. Inc. - Defense World
4DMT to Participate in Upcoming Investor Conferences | FDMT Stock News - GuruFocus
4DMT to Participate in Upcoming Investor Conferences - Eagle-Tribune
4DMT Leadership to Present Latest Biotech Advances at Two Major Healthcare Conferences in June - Stock Titan
4D Molecular Therapeutics (NASDAQ:FDMT) Receives Sell (E+) Rating from Weiss Ratings - Defense World
Millennium Management LLC Acquires 1,337,497 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics’ SWOT analysis: gene therapy stock faces durability challenges amid pipeline progress - Investing.com
Deutsche Bank AG Sells 560,784 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Acquired by Northern Trust Corp - Defense World
BNP Paribas Financial Markets Makes New Investment in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Spotlight On 3 Penny Stocks With Market Caps Under $500M - Yahoo Finance
Jane Street Group LLC Increases Stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by Price T Rowe Associates Inc. MD - Defense World
Dimensional Fund Advisors LP Cuts Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4DMT Boosts Talent Acquisition: 31,800 RSUs Granted as Biotech Firm Accelerates Growth - Stock Titan
FY2025 EPS Estimates for FDMT Decreased by Cantor Fitzgerald - Defense World
HC Wainwright Analysts Boost Earnings Estimates for FDMT - Defense World
Chardan Adjusts Price Target on 4D Molecular Therapeutics to $25 From $28, Maintains Buy Rating - marketscreener.com
Hsbc Holdings PLC Grows Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Barclays Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $38.00 - Defense World
The Goldman Sachs Group Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $44.00 - Defense World
Chardan Capital Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $25.00 - Defense World
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates - MSN
Wells Fargo & Company MN Boosts Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Contrasting Genfit (NASDAQ:GNFT) & 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (E+)” Rating at Weiss Ratings - Defense World
Barclays Adjusts Price Target for 4D Molecular (FDMT) | FDMT Sto - GuruFocus
RBC Cuts Price Target on 4D Molecular Therapeutics to $26 From $35, Keeps Outperform, Speculative Risk - marketscreener.com
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by Barclays PLC - The AM Reporter
Barclays Adjusts Price Target for 4D Molecular (FDMT) | FDMT Stock News - GuruFocus
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $26.71 Consensus Price Target from Brokerages - Defense World
4D Molecular Therapeutics Reports Increased Quarterly Loss - TipRanks
4D Molecular Therapeutics Inc Reports Q1 2025 EPS of -$0.86, Missing Estimates; Revenue Falls Short at $14,000 - GuruFocus
4D Molecular Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
4D Molecular Therapeutics, Inc. SEC 10-Q Report - TradingView
4D Molecular Therapeutics Enrolls First Patients in Phase 3 Clinical Trials for 4D-150 in Wet AMD, Receives FDA RMAT Designation for DME - Nasdaq
4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones - GlobeNewswire
FDMT4D Molecular Therapeutics Inc. Latest Stock News & Market Updates - Stock Titan
Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference - Yahoo Finance
Raymond James Financial Inc. Invests $629,000 in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Gene Therapy in Ophthalmology Industry Report 2025-2035: Global Market Poised for Growth as Inherited Retinal Disease Cases Surge Worldwide - GlobeNewswire Inc.
Financial Comparison: 4D Molecular Therapeutics (NASDAQ:FDMT) and Cardiff Oncology (NASDAQ:CRDF) - Defense World
4D Molecular Therapeutics Inc expected to post a loss of 86 cents a shareEarnings Preview - TradingView
Are 4D Molecular Therapeutics Inc’shares a good deal? - uspostnews.com
Synhale Therapeutics Acquires Telaglenastat, Accelerates Development for Pulmonary Hypertension Treatment - The Malaysian Reserve
4D Molecular's Macular Edema Treatment Gets Regenerative Medicine Designation from FDA - marketscreener.com
4D Molecular Therapeutics' 4D-150 Receives RMAT Designation For Diabetic Macular Edema - Nasdaq
4D Molecular wins RMAT status for eye therapy (FDMT:NASDAQ) - Seeking Alpha
4D Molecular Therapeutics receives RMAT designation for 4D-150 for the treatment of diabetic macular edema - Ophthalmology Times
4 D Molecular Therapeutics Inc (FDMT) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):